ATAI
NasdaqGMAtaiBeckley Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 21 recent filings. 18 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
HERSHBERG ROBERT Director | Option exercise | 48.86K | $1.35 | $65,958.30 | 2026-07-07 |
HERSHBERG ROBERT Director | Option exercise | 51.14K | $1.35 | $69,041.70 | 2026-07-07 |
HERSHBERG ROBERT Director | Sell (open market) | 100K | $4.96 | $496,000.00 | 2026-07-07 |
HERSHBERG ROBERT Director | Option exercise | 48.86K | $0.00 | — | 2026-07-07 |
HERSHBERG ROBERT Director | Option exercise | 51.14K | $0.00 | — | 2026-07-07 |
Craig Kevin James Chief Medical Officer | Option exercise | 33.05K | $1.50 | $49,576.50 | 2026-06-25 |
Craig Kevin James Chief Medical Officer | Option exercise | 9.53K | $1.18 | $11,243.04 | 2026-06-25 |
Craig Kevin James Chief Medical Officer | Sell (open market) | 42.58K | $4.51 | $192,031.29 | 2026-06-25 |
Craig Kevin James Chief Medical Officer | Option exercise | 33.05K | $0.00 | — | 2026-06-25 |
Craig Kevin James Chief Medical Officer | Option exercise | 9.53K | $0.00 | — | 2026-06-25 |
Kochendoerfer Gerd Chief Operating Officer | Option exercise | 50K | $1.60 | $80,000.00 | 2026-06-26 |
Kochendoerfer Gerd Chief Operating Officer | Sell (open market) | 50K | $5.00 | $250,000.00 | 2026-06-26 |
Kochendoerfer Gerd Chief Operating Officer | Option exercise | 50K | $0.00 | — | 2026-06-26 |
Angermayer Christian Director, 10% Owner | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
Braunstein Scott Director | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
Braunstein Scott Director | Grant / award | 86.1K | $0.00 | — | 2026-06-04 |
Fischer Laurent Director | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
HERSHBERG ROBERT Director | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
Hoffman John Francis Director | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
Kalali Amir H Director | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
Smiley Andrea Heslin Director | Grant / award | 121.97K | $0.00 | — | 2026-06-04 |
Source: SEC EDGAR Forms 4/4A (CIK 2081043). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
I personally think $ATAI sold becuase they know that cannot compete with $DFTX or $CMPS short term. Those two are going to take the spotlight and investors and $ATAI would have run out of money. I bet $LLY will take BPL-003 to market, but $ATAI would have not been able to
$ATAI The spin from the CEO about selling out is now the importance of getting these valuable meds to patients as quick as possible (he doesn't convenientlymention getting his $30+ million as soon as possible or CA his $500+ mil) . Ok, but isnt that what we were told repeatedly that Ferring was for when they invested? An experienced European Pharma partner to commercialize the assets? Oh well, I hope the deal fails or is sweetened but now that I know what lying scoundrals these guys are I think I'll probably be relieved to be moving on.
$ATAI I'm not saying this is the ONLY factor behind $ATAI's recent price action… there are always multiple forces at work. But one thing people overlook is this: Today's resistance can simply be yesterday's winners taking profits. Every share sold has to be absorbed by a buyer. Once that supply starts drying up, resistance often weakens. Nothing is guaranteed, but if demand stays strong after that selling pressure is absorbed, the path to $7.50+ can become a lot less crowded. I have 295 $7 calls and expect slightly more upside in the next few weeks.
$ATAI I had only few shares and have cashed out for a decent profit. I wish to all of you who are staying all the good luck and a maximum possible reward for your patience and guts. 🙋♂️🤞
@GlobalMarketBulletin Wrong! $ATAI "Atai Life Sciences N.V. ATAI +0.98% 55 experienced a downgrade in its analyst rating from Buy to Hold by Canaccord Genuity, with a new price target set at $8.00. This marks a significant shift in sentiment for the company"...GURUFOCUS.
@GlobalMarketBulletin The three-digit upside potential mentioned, which analysts have been talking about… well, I suppose we can forget about that now…Or perhaps not? ... The big advantage now is that the share price is presumably protected on the downside, and a fall below 6.75 seems rather unlikely... On the upside, the share price currently appears capped at just under 8. However, the $LLY takeover bid for $ATAI still needs to be approved by the Ataibeckely- shareholders’ meeting… A lot can still happen between now and then… ...For example, other bidders could emerge… Or the shareholders might simply reject it...
$ATAI AtaiBeckley N.V. (ATAI) is gaining attention after joining major Russell indexes and receiving a $17 analyst price target. Could this mental health biotech stock under $10 deliver triple-digit upside? https://globalmarketbulletin.com/is-ataibeckley-atai-a-smart-psychedelic-medicine-stock-to-buy-now/
$ATAI $LRMR $SABS $VSTM $SOC Wall Street sees triple-digit upside in several of these stocks under $10. Discover the biotech, healthcare, energy, and cryptocurrency names investors are closely watching. https://globalmarketbulletin.com/10-stocks-under-10-analysts-believe-could-soar-200/
$ATAI Acceptance of this ridiculous offer does, after all, depend on the approval of the company’s shareholders and owners, doesn’t it? I wouldn’t be at all surprised if this offer – which is clearly too low – were to be rejected by a majority at the next annual general meeting. I myself (with over 20 years’ experience in Big Pharma) will be voting against it. The enormous potential is surely also recognised by other pharmaceutical companies willing to pay, and is certainly valued much more highly by them. I’m actually in favour of carrying on without a partner at all.
$ATAI the 2 big questions according to Google: https://www.google.com/search?q=what+are+the+chances+the+atai+beckley+eli+lilly+buyout+gets+voted+down&sca_esv=e441c5567561f5e6&sxsrf=APpeQnson43EoBl152gC4fBDch7kCVlHFA%3A1784356737758&source=hp&ei=gR9baq2gLM6OseMPz4Hq2AI&iflsig=ABILxe8AAAAAalstkbsVS38q5pN_yqfX193mbsOdvaYI&oq=wh&gs_lp=Egdnd3Mtd2l6IgJ3aCoCCAAyBBAjGCcyBBAjGCcyBBAjGCcyCxAAGIAEGIoFGJECMgsQABiABBiKBRiRAjIKEAAYgAQYigUYQzIKEAAYgAQYigUYQzIFEAAYgAQyBRAAGIAEMgUQABiABEiEHFAAWIMDcAB4AJABAJgBigGgAegBqgEDMS4xuAEByAEA-AEBmAICoAL5AcICEBAAGIAEGIoFGEMYsQMYgwHCAhAQLhiABBiKBRhDGLEDGIMBwgIQEC4YgAQYigUYQxjHARjRA8ICCxAuGIMBGLEDGIAEwgIOEAAYgAQYigUYjQYYsQOYAwCSBwMxLjGgB-AVsgcDMS4xuAf5AcIHBTItMS4xyAcNgAgB&sclient=gws-wiz https://www.google.com/search?q=what+are+the+chances+the+atai+beckley+eli+lilly+buyout+gets+a+better+offer&sca_esv=e441c5567561f5e6&sxsrf=APpeQnuGdyB6Oa6z7dbumOmLX13Utz8a2Q%3A1784356745639&source=hp&ei=iR9bavmXIfebseMP7sbt2AU&iflsig=ABILxe8AAAAAalstmZ80SJorWfdyubQtpSgEAB4x7eJg&oq=wha&gs_lp=Egdnd3Mtd2l6IgN3aGEqAggBMgQQIxgnMgQQIxgnMgQQIxgnMgUQABiABDIOEAAYgAQYigUYsQMYgwEyBRAAGIAEMgUQABiABDILEAAYgAQYsQMYgwEyERAuGIAEGLEDGIMBGMcBGNEDMgUQABiABEj9FFAAWPgCcAB4AJABAJgBhAGgAdQCqgEDMC4zuAEByAEA-AEBmAIDoALpAsICEBAAGIAEGIoFGEMYsQMYgwHCAgsQLhiDARixAxiABMICDhAAGIAEGIoFGI0GGLEDwgIREC4YgAQYigUYjQYYsQMYgwHCAhEQABiABBiKBRiNBhixAxiDAcICCBAAGIAEGLEDmAMAkgcDMC4zoAeaILIHAzAuM7gH6QLCBwUyLTIuMcgHD4AIAQ&sclient=gws-wiz
$ATAI there is no more 10x upside on this stock.. I've sold all my position yesterday, I'm not sure of the chances of getting more. Sold at 60% profit and deployed that profit into $CMPS. There is a reason they agreed on this price that we might never know.
$ATAI Possible but unlikely. Lilly appears to have moved decisively and is a good fit. J&J already has Spravato so why compete against their own prroduct. I owudl think the chance of any competing bid is around 15–25% with AbbVie most likely if that was to happen as they have interest in the space. I assume the Atai board has contacted multiple potential buyers during its sale process.
Latest news
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued
Eli Lilly's $3.8bn psychedelics bet is built on British science
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover
Sector Update: Healthcare Stocks Gain Late Afternoon
AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout
Sector Update: Healthcare Stocks Gain Thursday Afternoon
Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline
🔎 Under the Radar: Psychedelic-Drug Stock Soars on Eli Lilly Deal
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.